// App-Quantinova.ai

P707 : Microbial signature of the colon is not associated with response to vedolizumab in Crohn’s disease

Researchers

Presenter

  • HagemanMD, I

Principal Investigators

  • Joustra, V

  • Li Yim, A

  • Davids, M

  • Henneman, P

  • Hakvoort, T

  • Probert, F

  • Satsangi, J

  • D'Haens, G

  • De Jonge, W

Medical Centers

  • Academic Medical Center AMC University of Amsterdam, Department of Gastroenterology & Hepatology, Amsterdam, The Netherlands

  • Academic Medical Center AMC University of Amsterdam, Tytgat Institute for Liver and Intestinal Research, Amsterdam, The Netherlands

  • Amsterdam UMC- University of Amsterdam, Genome Diagnostics Laboratory- Department of Human Genetics, Amsterdam, The Netherlands

  • Amsterdam UMC- University of Amsterdam, Laboratory of Experimental Vascular Medicine- Academic Medical Center, Amsterdam, The Netherlands

  • Oxford University, Department of Chemistry- Chemistry Research Laboratory- Mansfield Road, Oxford, United Kingdom

  • Oxford University, Translational Gastroenterology Unit- NIHR Oxford Biomedical Research Centre- Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

  • On behalf of the EPIC-Pioneer consortiu

Locations

  • Netherlands

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • C reactive protein

  • Faecal calprotectin

Drug/Treatment

  • Entyvio

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved